High-Dose TOREMIFENE for non-steroidal AI failure
Phase 2
- Conditions
- Recurrent breast cancer
- Registration Number
- JPRN-UMIN000003178
- Lead Sponsor
- Hiroshima Breast Cancer Study Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Contraindication case for toremifene. (2)Case with inflammatory breast cancer or bilateral breast cancer. (3)Case with active other malignancies. (4)Case with life-threatening metastasis. (5)Case with past history of drug allergy or hypersensitivity. (6)Case with past use of anti-estrogen drug. (7)Case judged inappropriate by physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method .Clinical benefit .Response Rate (CR, PR)
- Secondary Outcome Measures
Name Time Method .TTP(Time to progression) .TTF(Time to treatment failure)